Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
ANZUP’s ENZA-p combination breakthrough for patients with metastatic castration-resistant prostate cancer
In a significant stride forward in treatment options for metastatic castration-resistant prostate cancer (mCRPC), a…
Ask Chat GPT about your radiation oncology treatment
Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be…
New AI model detects 90% of lymphatic cancer cases
Medical image analysis using AI has developed rapidly in recent years. Now, one of the…
ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients previously treated with endocrine therapy
- ASCO 2024: Improved progression-free survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer
- ENDO 2024: Almost 20% of breast cancer survivors may experience excess weight gain
- ENDO 2024: High insulin levels contribute to worse outcomes for Black women with triple-negative breast cancer
AGITG Annual Scientific Meeting 2020 Review
By Erin Burgess, AGITG For 2020, the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting (ASM) went virtual for the…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.